未登录

K

Kyle Wagner

university of north carolina

H指数:16

被引数:856

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma (vol 12, pg 1544, 2018)

IF16

2024-05-280

OA

Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model

IF7.7

2023-02-010

OAAI

Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment

ACTA BIOMATERIALIA

IF9.6

2022-08-013

OAAI

3D printed drug-loaded implantable devices for intraoperative treatment of cancer

JOURNAL OF CONTROLLED RELEASE

IF11.5

2022-04-0113

OAAI

Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models

ACTA BIOMATERIALIA

IF9.6

2021-04-0146

OAAI

Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo

IF12.1

2020-01-2318

OAAI

Cancer Immunotherapy Is More Effective in Irradiated Tumors in Preclinical Mouse Model of Melanoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-010

PREAI

Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion

ADVANCED SCIENCE

IF14.1

2019-08-1316

OAAI

Quantification and downstream analysis of circulating tumor cells isolated using CapioCyte™ liquid biopsy

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models

IF12.9

2018-07-0172

OAAI

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

定制的预靶向纳米放射免疫疗法治疗非霍奇金淋巴瘤

IF16

2018-01-2642

OAAI

Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models

JOURNAL OF MATERIALS CHEMISTRY B

IF5.7

2017-01-0150

OAAI

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2016-11-0124

PREAI

Optimization of Polymeric Nanoparticle Size for Use in Chemoradiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2016-10-010

OAAI

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of a Mitomycin C Prodrug, for Use in Chemoradiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2016-10-012

PREAI

Direct Observation of Early-Stage High-Dose Radiotherapy-Induced Vascular Injury via Basement Membrane-Targeting Nanoparticles

IF12.1

2015-11-186

OAAI

Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors

IF12.9

2015-05-0160

OAAI

Local iontophoretic administration of cytotoxic therapies to solid tumors

对实体瘤进行细胞毒性疗法的局部离子电渗给药

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2015-02-0461

OAAI

Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery

IF5.1

2015-01-0134

OAAI